BioSpace News Archive

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the fourth quarter and full year 2022.

Edgewise Therapeutics, Inc., (Nasdaq: EWTX) today announced the publication of the article, “Modulating fast skeletal muscle contraction protects skeletal muscle in animal models of Duchenne muscular dystrophy,” in the Journal of Clinical Investigation.

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company primarily focused on cardiometabolic diseases, today announced financial results for the year ended December 31, 2022.

INVO Bioscience, Inc., a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture procedure it enables, announced preliminary financial results for the fourth quarter and year ended December 31, 2022.

Revelation Biosciences Inc., a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, reported its year end 2022 financial results and highlighted recent corporate progress.

Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, today reported financial results for the fourth quarter and full year of 2022.

Molecular Templates, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.

Eisai Co., Ltd. and Biogen Inc. announced that three additional detailed analyses from the Phase IIb clinical study, evaluating the efficacy and safety of lecanemab for mild cognitive impairment due to Alzheimer’s disease and mild AD, were published in the peer-reviewed journals.

Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, announced that it will for the first time share new data for its revolutionary dermatology platform with the international regenerative aesthetic community.

Halberd Corporation (OTC PINK:HALB) and Mississippi State University (MSU) signed an agreement outlining the testing in pre-clinical models which will be conducted at MSU.